Regeneron Pharmaceuticals
REGN
1,272 hedge funds and large institutions have $81.4B invested in Regeneron Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 184 funds opening new positions, 443 increasing their positions, 443 reducing their positions, and 68 closing their positions.
171% more first-time investments, than exits
New positions opened: 184 | Existing positions closed: 68
8% more capital invested
Capital invested by funds: $75.1B → $81.4B (+$6.26B)
8% more funds holding
Funds holding: 1,177 → 1,272 (+95)
0.99% more ownership
Funds ownership: 85.45% → 86.44% (+0.99%)
0% more repeat investments, than reductions
Existing positions increased: 443 | Existing positions reduced: 443
14% less funds holding in top 10
Funds holding in top 10: 29 → 25 (-4)
35% less call options, than puts
Call options by funds: $1.25B | Put options by funds: $1.93B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.08B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$392M |
| 3 |
Millennium Management
New York
|
+$200M |
| 4 |
Amundi
Paris,
France
|
+$188M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$181M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.23B |
| 2 |
SGA
Sustainable Growth Advisers
Stamford,
Connecticut
|
-$345M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$333M |
| 4 |
BlackRock
New York
|
-$202M |
| 5 |
Neuberger Berman Group
New York
|
-$199M |
REGN Hedge Fund Activity: Q4 2023 in Review
1,272 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2023, worth a combined $81.4B — up 8.3% from $75.1B a quarter earlier.
Buyers outnumbered sellers: 184 funds opened new REGN positions and 68 closed out — a net gain of 116 holders — while 443 added to existing stakes and 443 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.08B. The largest seller was T. Rowe Price Associates, cutting an estimated $1.23B.
- 1,272 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2023, up from 1,177 in Q3 2023.
- Funds reported $81.4B of Regeneron Pharmaceuticals stock for Q4 2023, up 8.3% quarter-over-quarter.
- 184 funds opened new Regeneron Pharmaceuticals positions in Q4 2023 and 68 closed out, a net change of +116 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $1.08B added.
- The largest Regeneron Pharmaceuticals seller in Q4 2023 was T. Rowe Price Associates, an estimated $1.23B sold.
Based on aggregated 13F filings for Q4 2023.